Varenicline and Bupropion: Soaring Again With EAGLES?
The Carlat Addiction Treatment Report, Volume 7, Number 7&8, November 2019
Topics: Addiction | Addiction Treatment | Bupropion | Chantix | Co-occurring disorders | Dual diagnosis | FDA Warnings | Medication | Pharmacology | Research | Research Update | Side Effects | Smoking Cessation | Smoking Cessation Agents | Substance Use | Substance use disorders | Suicidality | Suicide | Tobacco | Varenicline | Wellbutrin
Nicholas Rosenlicht, MD.
Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
This research update unpacks the details behind the landmark “EAGLES” trial (Evaluating Adverse Events in a Global Smoking Cessation Study), which led to the removal of the varenicline black box warning.